Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Akorn Inc
(NQ:
AKRX
)
0.0900
USD
UNCHANGED
Last Price
Updated: 7:59 PM EDT, May 29, 2020
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Akorn Inc
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success
May 20, 2020
Continues Operations as Usual, Delivering Safe and Effective Products to Customers and Patients
From
PR Newswire
Akorn Provides First Quarter 2020 Results
May 11, 2020
From
GlobeNewswire News Releases
Thinking about buying stock in Myomo, Microvision, Akorn Inc, Callon Petroleum, or Recon Technology?
May 01, 2020
InvestorsObserver issues critical PriceWatch Alerts for MYO, MVIS, AKRX, CPE, and RCON.
From
PR Newswire
Enphase Energy and Paylocity Set to Join S&P MidCap 400; Core Laboratories and Meredith to Join S&P SmallCap 600
April 27, 2020
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Friday, May 1:
From
PR Newswire
Akorn Provides Update on Sale Process
April 01, 2020
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it no longer has any bids in the Sale Process that are sufficient to pay all obligations under its term loan...
From
PR Newswire
Akorn Provides Fourth Quarter and Full Year 2019 Results
February 26, 2020
From
GlobeNewswire News Releases
Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business
February 12, 2020
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced it has reached an agreement with certain of its lenders to extend the standstill period. The agreement defines a...
From
PR Newswire
Akorn Continues Negotiations with Lenders
February 10, 2020
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today confirmed that negotiations with certain of its lenders are ongoing following the expiration of its standstill agreement on...
From
PR Newswire
Akorn Announces Extension of Standstill Agreement
December 16, 2019
From
GlobeNewswire News Releases
Akorn to Present at the Credit Suisse Healthcare Conference
November 05, 2019
From
GlobeNewswire News Releases
Akorn Provides Preliminary Third Quarter 2019 Results
October 31, 2019
Updates net loss and affirms net revenue and adjusted EBITDA guidance
From
GlobeNewswire News Releases
Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%
October 14, 2019
From
GlobeNewswire News Releases
Akorn to Report Third Quarter 2019 Financial Results and Host Conference Call
October 14, 2019
From
GlobeNewswire News Releases
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%
August 26, 2019
From
GlobeNewswire News Releases
Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call
July 11, 2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, August 1, 2019 outlining its...
From
GlobeNewswire News Releases
Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%
June 28, 2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%.
From
GlobeNewswire News Releases
Akorn Receives FDA Warning Letter
June 25, 2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter from the U.S. Food and Drug Administration (FDA) related to the inspection of...
From
GlobeNewswire News Releases
Akorn to Present at the Jefferies 2019 Global Healthcare Conference
May 30, 2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019...
From
GlobeNewswire News Releases
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
May 20, 2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug...
From
GlobeNewswire News Releases
NASDAQ:AKRX Long Term Investor Alert: Investigation of Potential Wrongdoing at Akorn, Inc.
May 20, 2019
San Diego, CA -- (SBWIRE) -- 05/20/2019 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Akorn, Inc..
From
SBWire - Latest Press Releases
Akorn to Present at the RBC Capital Markets Healthcare Conference
May 20, 2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC Capital Markets Healthcare Conference on Wednesday, May 22,...
From
GlobeNewswire News Releases
Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance
May 07, 2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the first quarter of 2019.
From
GlobeNewswire News Releases
Report: Developing Opportunities within Hawaiian Electric Industries, Landstar System, Ladenburg Thalmann Financial Services, and Akorn — Future Expectations, Projections Moving into 2019
May 02, 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hawaiian Electric...
From
GlobeNewswire News Releases
Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX)
April 22, 2019
Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX)
From
Business Wire News Releases
FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC
April 22, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the...
From
GlobeNewswire News Releases
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc.
April 22, 2019
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Akorn, Inc. (“Akorn”...
From
GlobeNewswire News Releases
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 22, 2019
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. (“Akorn” or “the Company”) (NASDAQ: AKRX) for violations of...
From
GlobeNewswire News Releases
Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI
April 19, 2019
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines listed below. If you have purchased or otherwise...
From
GlobeNewswire News Releases
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
April 18, 2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug...
From
GlobeNewswire News Releases
Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
April 18, 2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug...
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.